Back

Comparative effectiveness of ticagrelor versus clopidogrel in older adults (≥75 years) with ST-segment elevation myocardial infarction: a target trial emulation study

31 August 2026 (10:45 - 10:53)
Organised by: Logo
Congress Presentation Part of: Cardiovascular disease in older adults: ageing, risk stratification, and outcomes Cardiovascular Disease in the Elderly ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Rongxin Guo

2nd Hospital of Tianjin Medical University, Tianjin (China)

3 More presentations in this session

Presentation thumbnail
Lipoprotein(a) and cardiovascular disease in individuals aged 70-100 years
Doctor B. Nordestgaard (Copenhagen, DK)
Abstract
Presentation thumbnail
Age-related amplification of inflammatory risk after percutaneous coronary Intervention: a 10-year large-sample prospective cohort study
Ms M. Liu (Beijing, CN)
Abstract
Presentation thumbnail
CVMI-age quantifies multidimensional cardiovascular aging and predicts cardiovascular events: a Chinese community-based cohort study
Doctor H. Xie (Beijing, CN)
Abstract

Access the full session

Session thumbnail
Cardiovascular disease in older adults: ageing, risk stratification, and outcomes

The Event

Event poster

ESC Congress 2026

31 August 2026 10:45 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of clopidogrel, ticagrelor, and prasugrel in an all-comers population of patients with ST-segment elevation myocardial infarction
31 August 2020
thumbnail
Congress Presentation
Intervention versus conservative treatment for very elderly patients with NSTEMI and frailty: a multi-center observational study
1 September 2025
thumbnail
Congress Presentation
Direct oral anticoagulants versus left atrial appendage closure in elderly patients (>80) with atrial fibrillation: results from a propensity matched analysis in real-life patients
28 August 2020
thumbnail
Congress Presentation
Managing dyslipidemia in the elderly: efficacy and safety of bempedoic acid in very high-risk patients
4 April 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources